Clinical Trials

Breast Neoplasms, Recurrence

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

350 enrolled

Triple Negative Breast Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06382142 2025-11-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

418 enrolled

Triple Negative Breast Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Breast Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06343948 2025-06-25

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

383 enrolled

HR+HER2- Breast Cancer

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

543 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

302 enrolled

Breast Neoplasms

NCT04400695 2024-01-24

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

366 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

420 enrolled

HER2-positive Advanced Breast Cancer

NCT00128310 2023-05-31

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

252 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT02574455 2022-06-15

ASCENT

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02730091 2021-02-01

VICTORIANE

Phase 3 Terminated

98 enrolled

Breast Neoplasms

NCT04665986 2020-12-14

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

50 enrolled

Breast Neoplasms

NCT01950182 2020-07-15

SYSUCC-002

392 enrolled

Breast Neoplasms

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

508 enrolled 13 charts

Breast Neoplasms

NCT02225470 2018-08-28

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

530 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT01007942 2017-04-05

BOLERO-3

569 enrolled 16 charts

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT00868634 2016-08-31

CARIN

600 enrolled

Breast Neoplasms

NCT00103233 2013-06-24

Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer

Breast Neoplasms

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

200 enrolled

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

NCT00146549 2009-11-02

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT00431106 2009-09-28

Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

144 enrolled

Breast Neoplasms

NCT00430001 2008-05-09

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

300 enrolled